Email Us
View Reports

United States Influenza Vaccine Market | Industry Analysis and Future Forecast (2018 - 2025)

  • ID : 4771587  |  
  • Published : Dec-2016  |  
  • Region : North America  |  
  • Pages : 122   |  
  • Publisher : DPI Research

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.

Major and Promising Vaccine covered in the report are as follows:

1. Fluzone High–Dose

2. Fluzone Quadrivalent

3. Intradermal (ID) Trivalent

4. Vaxigrip

5. Fluarix Quadrivalent

6. Flulaval Quadrivalent

7. Fluenz Tetra

8. FluMist Quadrivalent

9. Flublok

10. VN–100

11. M–001

12. VAX–2012Q

13. TAK – 850

14. Flucelvax Quadrivalent

15. Afluria Quadrivalent

16. Agrippal

17. Fluad

18. Fluvirin

19. Fluvax

Key Companies Covered in the Report are as follows

1. Sanofi Pasteur

2. GlaxoSmithKline(GSK)

3. Seqirus

4. AstraZenecca

5. Protein Sciences Corporation

6. Novavax

7. Daiichi–Sankyo

8. Mitsubishi Tanabe Pharma

9. BiondVax Pharmaceuticals Ltd

10. VaxInnate

Table of Contents

1. Executive Summary

2. United States Influenza Vaccine Market & Forecast

3. United States Number of Persons Vaccinated with Influenza Vaccine

3.1 Number of Children Vaccinated

3.2 Number of Adults Vaccinated

4. United States Influenza Vaccine Market Drivers and Barriers

4.1 Market Drivers

4.2 Market Barriers

5. United States Influenza Vaccine Production & Distribution

5.1 Vaccine Choices Remain Available for Patients, Providers

5.2 Influenza Vaccine Price Trends

5.2.1 Pediatric Influenza Vaccine Price Trends

5.2.2 Adult Influenza Vaccine Price Trends

5.3 Influenza Vaccine Production, Supply, and Allocation

5.4 Influenza Vaccine Distribution & Demand

5.5 Influenza Vaccine Effectiveness

5.6 Managing Influenza with Diagnostic Resources

5.7 Distribution Method of Influenza Vaccination

6. United States Influenza Vaccine Market – Regulatory Landscape

7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations

7.1 Merger & Acquisitions

7.2 Collaboration Deal

7.3 Licensing, Exclusive & Distribution Agreement Deal

7.3.1 Licensing Agreement

7.3.2 Exclusive Agreement

7.3.3 Distribution Agreement

8. Influenza Vaccine – Pipeline Assessment

8.1 Promising Vaccine in Clinical Development

8.2 Promising Vaccine in Early–Stage Development

9. Influenza Vaccine – Clinical Trials Assessment by Phase and Trial Status

9.1 Year 2016

9.2 Year 2015

9.3 Year 2014

9.4 Year 2013

10. Key Companies Analysis

10.1 Sanofi Pasteur

10.1.1 Business Overview

10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook

10.1.2.1 Fluzone High–Dose Vaccine

10.1.2.2 Fluzone Quadrivalent Vaccine

10.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine

10.1.2.4 Vaxigrip Vaccine

10.1.3 Influenza Vaccine Sales Analysis

10.2 GlaxoSmithKline (GSK)

10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook

10.2.1.1 Fluarix Quadrivalent

10.2.1.2 Flulaval Quadrivalent

10.2.2 Influenza Vaccine Sales Analysis & Forecast

10.3 AstraZeneca

10.3.1 Business Overview

10.3.2 AstraZeneca – Influenza Vaccine Outlook

10.3.2.1 Fluenz Tetra/FluMist Quadrivalent

10.3.3 Influenza Vaccine Sales Analysis

10.4 Protein Sciences Corporation

10.4.1 Business Overview

10.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook

10.4.2.1 Flublok

10.5 Seqirus (CSL Limited)

10.5.1 Business Overview

10.5.2 Seqirus – Influenza Vaccine Outlook

10.5.2.1 Flucelvax Quadrivalent

10.5.2.2 Afluria Quadrivalent

10.5.2.3 Agrippal

10.5.2.4 Fluad

10.5.2.5 Fluvirin

10.5.2.6 Fluvax

List of Tables

Table 5–1: United States Influenza Vaccine Available,2016 – 17

Table 5–2: United States – Pediatric Influenza Vaccine Price, 2016 – 2017

Table 5–3: United States – Adult Influenza Vaccine Price, 2016 – 2017

Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation

Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017

Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016

Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015

Table 5–8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005 – 2016

Table 5–9: Managing Influenza with Diagnostic Resources

Table 5–10: Distribution of Influenza Vaccination

Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 7–1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015

Table 7–2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016

Table 7–3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016

Table 7–4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016

Table 7–5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016

List of Figures

Figure 2 1: United States – Influenza Vaccine Market (Million US$),2010 – 2015

Figure 2 2: United States – Forecast for Influenza Vaccine Market (Million US$),2016 – 2022

Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 3 2: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 3 3: United States – Number of Children Vaccinated(Thousand),2010 – 2015

Figure 3 4: United States – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022

Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2015

Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2016 – 2022

Figure 5 1: United States – Influenza Vaccine Doses Distributed, By Season(Million),2010 – 2016

Figure 10 1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US$),2011 – 2015

Figure 10 2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022

Figure 10 3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015

Figure 10 4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022

Figure 10 5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?